CreativeOne Wealth LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 322.3% during the third quarter, Holdings Channel.com reports. The fund owned 16,162 shares of the biopharmaceutical company’s stock after acquiring an additional 12,335 shares during the period. CreativeOne Wealth LLC’s holdings in Gilead Sciences were worth $997,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Gilead Sciences by 1.2% in the third quarter. BlackRock Inc. now owns 128,460,733 shares of the biopharmaceutical company’s stock valued at $7,924,739,000 after purchasing an additional 1,523,122 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 112,087,271 shares of the biopharmaceutical company’s stock valued at $6,914,663,000 after buying an additional 1,691,194 shares in the last quarter. State Street Corp lifted its holdings in shares of Gilead Sciences by 2.2% during the 3rd quarter. State Street Corp now owns 59,240,350 shares of the biopharmaceutical company’s stock worth $3,654,537,000 after acquiring an additional 1,293,414 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after acquiring an additional 6,410,047 shares in the last quarter. 78.72% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Cowen boosted their price objective on shares of Gilead Sciences from $90.00 to $95.00 in a research report on Friday, February 10th. Oppenheimer upped their price objective on Gilead Sciences from $95.00 to $105.00 in a research report on Thursday, December 1st. Piper Sandler lifted their target price on Gilead Sciences from $111.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $75.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 3rd. Finally, SVB Leerink lifted their price target on shares of Gilead Sciences from $81.00 to $91.00 and gave the company a “market perform” rating in a report on Friday, February 3rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.40.
Insider Transactions at Gilead Sciences
Gilead Sciences Stock Up 1.3 %
Shares of GILD opened at $79.77 on Wednesday. The stock’s 50-day moving average price is $83.65 and its two-hundred day moving average price is $78.28. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $89.74. The company has a market capitalization of $99.48 billion, a PE ratio of 21.85, a PEG ratio of 0.95 and a beta of 0.38. The company has a current ratio of 1.29, a quick ratio of 1.15 and a debt-to-equity ratio of 1.14.
Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The company had revenue of $7.39 billion during the quarter, compared to the consensus estimate of $6.63 billion. During the same period last year, the company earned $0.69 earnings per share. The firm’s revenue was up 2.0% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post 6.84 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Wednesday, March 15th will be paid a $0.75 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.76%. The ex-dividend date is Tuesday, March 14th. Gilead Sciences’s dividend payout ratio is currently 80.00%.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.